Oxidized glycerophosphatidylcholines in diabetes through non-targeted metabolomics: Their annotation and biological meaning
| Autor: | Bartlomiej Kalaska, Jitka Široká, Coral Barbas, Adam Kretowski, Michal Ciborowski, Joanna Godzien, Edyta Adamska-Patruno |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Clinical Biochemistry Overweight Bioinformatics 030226 pharmacology & pharmacy 01 natural sciences Biochemistry Analytical Chemistry 03 medical and health sciences 0302 clinical medicine Metabolomics Insulin resistance Lipid oxidation Tandem Mass Spectrometry medicine Humans Glucose homeostasis Prediabetes Chromatography Chemistry 010401 analytical chemistry nutritional and metabolic diseases Type 2 Diabetes Mellitus Cell Biology General Medicine Middle Aged medicine.disease Glycerylphosphorylcholine 0104 chemical sciences Diabetes Mellitus Type 2 Metabolome medicine.symptom Oxidation-Reduction Body mass index Chromatography Liquid |
| Zdroj: | Journal of Chromatography B. 1120:62-70 |
| ISSN: | 1570-0232 |
| DOI: | 10.1016/j.jchromb.2019.04.053 |
| Popis: | Lipid oxidation is one of the most important processes occurring in living cells and has been investigated through stable end-products. Currently, new insights into many physiological and pathophysiological processes provide a measurement of the first products of oxidation, e.g., oxidized glycerophosphatidylcholines (oxGPCs). Here, we evaluate the capacity of untargeted global metabolomics to measure oxGPCs in serum samples. This evaluation covered analytical reproducibility and data quality as well as the ability to capture metabolic alterations in diverse conditions. The analytical evaluation was performed based on the quality control samples, while the comparative analysis was based on the model of the development of type 2 diabetes mellitus (T2DM). The novelty of this approach arises not only from the measurement of oxGPCs instead of lipid peroxide-derived aldehydes but also from the stratification of the patients according to body mass index (BMI). Such a scenario was dictated by the fact that, despite the well-known relationship between obesity and T2DM development, there are lean individuals suffering from T2DM as well as obese people with normal glucose homeostasis. Our results provided evidence to support the ability of nontargeted metabolomics to measure oxGPCs. Comparative analysis of measured oxGPCs revealed differences in the level of oxGPCs either between different stages of disease development (insulin resistance, prediabetes) or BMI groups (normal weight, overweight, obese). The obtained results provided new insights into the metabolic processes leading to the development of T2DM and opened new paths in the investigation of the impact of body mass in T2DM progress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect